Low dose cabergoline induced interstitial pneumonitis

Area of Science:

• Pulmonology
• Neurology
• Pharmacology

Background:

• Dopaminergic anti-Parkinson drugs, specifically ergolines, are known causes of pleuropulmonary disease.
• A potential link between ergolines, asbestos exposure, and pleural pathology has been suggested.
• Idiopathic Parkinson's disease patients often have complex medication regimens.

Observation:

• A patient with Parkinson's disease on low-dose cabergoline developed a febrile illness.
• The patient presented with widespread bilateral lung infiltrations unresponsive to antibiotics.
• Bronchoalveolar lavage and lung biopsy indicated a hypersensitivity-like interstitial lung disease.

Findings:

• The patient's lung condition significantly improved within two months after cabergoline withdrawal.
• This suggests a previously undescribed adverse lung reaction to cabergoline.
• The reaction was characterized by interstitial lung disease without the typical pleural changes.

Implications:

• Cabergoline may induce interstitial lung disease as an adverse effect.
• This finding expands the known spectrum of cabergoline-induced pulmonary toxicity.
• Further investigation into cabergoline's pulmonary effects, especially in patients with potential risk factors, is warranted.